Publications

Journal Article Review Ppublish 7 citations

PubMed: 35398162 DOI: 10.1016/j.pcad.2022.04.001

TAVR - From inoperable to younger, lower-risk patients: A slippery slope?

Prog Cardiovasc Dis 72:41-53

Authors: Axel Unbehaun, Mohamed Abdullah, Amit Hooda, Maheedhar Gedela, Joerg Kempfert, Christoph Klein, Gilbert H L Tang

Affiliations

  • Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
  • Department of Cardiovascular Surgery, Mount Sinai Health System, New York, NY, USA.
  • Division of Cardiology, Mount Sinai Hospital, New York, NY, USA.
  • Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
  • Department of Internal Medicine - Cardiology, German Heart Center Berlin, Berlin, Germany.
  • Department of Cardiovascular Surgery, Mount Sinai Health System, New York, NY, USA.

Abstract

Despite current valve guidelines recommending both transcatheter and surgical aortic valve replacement (TAVR and SAVR, respectively) in patients with symptomatic severe aortic stenosis (AS), TAVR has recently become the preferred treatment over SAVR, driven by its minimal invasiveness, faster recovery and earlier improvement in quality of life. However, several limitations and unresolved issues remain with TAVR, including stroke, conduction system disorder, durability, bicuspid anatomy, coronary reaccess and lifetime management with aortic valve reintervention. Our review aims to highlight the above issues and discuss them in depth, to demonstrate the complementary role of TAVR and SAVR in the treatment of AS.

MeSH

Cardiovascular Diseases, Aortic Valve, Transcatheter Aortic Valve Replacement, Therapeutics, Surgical Aortic Valve Replacement

Cited by